Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com.
| Website | http://www.skyhawktx.com |
| Revenue | $9.5 million |
| Employees | 78 (57 on RocketReach) |
| Founded | 2016 |
| Phone | +61 78580041 |
| Technologies |
JavaScript
,
HTML
,
PHP
+13 more
(view full list)
|
| Industry | Biotechnology Research, Construction, Real Estate, Landscaping, Transportation |
| Keywords | Rna Modification, Rna Based Therapies, Rna Therapeutics, Small Molecule Therapeutics, Small Molecule Drugs, Gene Expression, Gene Regulation, Drug Discovery, Drug Development, Oligonucleotide Therapeutics, Molecular Medicine, Precision Medicine, Pharmaceutical Research, Novel Therapeutics, Innovative Medicines, Genetic Engineering, Biotechnology, Epigenetics |
| Competitors | Regeneron, Alnylam Pharmaceuticals, CRISPR Therapeutics, Moderna Therapeutics, Pliant Therapeutics, Editas Medicine, Silence Therapeutics plc, Akcea Therapeutics, NantKwest +49 more (view full list) |
Looking for a particular Skyhawk Therapeutics employee's phone or email?
Skyhawk Therapeutics Questions
The Skyhawk Therapeutics annual revenue was $9.5 million in 2026.
Kathleen McCarthy is the Co-founder and Distinguished Senior Scientist of Skyhawk Therapeutics.
57 people are employed at Skyhawk Therapeutics.
Top Skyhawk Therapeutics Employees
-
35+
-
35
-
Kyle Dow
Chief Financial Officer at Skyhawk Therapeutics
Boston, MA, US23 -
Masoud Mokhtarani
SVP Clinical Development at Skyhawk Therapeutics
San Diego, CA, US25 -
25
-
25+
-
Marykate Flaherty
EVP Finance at Skyhawk Therapeutics
Boston, MA, US35+ -
Maggie Beaudoin
VP of Finance at Skyhawk Therapeutics
Boston, MA, US25
Related Companies
